Chronic kidney disease and hypothalamic-pituitary axis dysfunction: The chicken or the egg?

Archives of Medical Research

Volumn 44, Issue 8, 2013, Pages 591-600

  Meuwese, Christiaan Lucas ^a,b   Carrero, Juan Jesús ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aldosterone; Cortisol; Estrogen; Hemodialysis; Inflammation; Prolactin; Testosterone; Thyroid; Triiodothyronine

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; HYDROCORTISONE; PRASTERONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; THYROID HORMONE;

CHRONIC KIDNEY DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOTHALAMIC PITUITARY AXIS DYSFUNCTION; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; NONHUMAN; PROLACTIN BLOOD LEVEL; REVIEW; SEXUAL DYSFUNCTION; SUBCLINICAL HYPOTHYROIDISM;

ALDOSTERONE; CORTISOL; ESTROGEN; HEMODIALYSIS; INFLAMMATION; PROLACTIN; TESTOSTERONE; THYROID; TRIIODOTHYRONINE;

ADRENAL CORTEX HORMONES; ADRENAL GLAND DISEASES; DISEASE PROGRESSION; GONADAL STEROID HORMONES; HUMANS; HYPOTHALAMIC DISEASES; INCIDENCE; PITUITARY DISEASES; RENAL INSUFFICIENCY, CHRONIC; THYROID HORMONES;

EID: 84889567613     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.009     Document Type: Review

References (137)

1. Jha V., Garcia-Garcia G., Iseki K., et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013, 382:260-272.
2. Ros S., Carrero J.J. Endocrine alterations and cardiovascular risk in CKD: is there a link?. Nefrologia 2013, 33:181-187.
3. Lo J.C., Chertow G.M., Go A.S., et al. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 2005, 67:1047-1052.
4. Song S.H., Kwak I.S., Lee D.W., et al. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant 2009, 24:1534-1538.
5. Kaptein E.M. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996, 17:45-63.
6. Montenegro J., Gonzalez O., Saracho R., et al. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996, 27:195-198.
7. Kreisman S.H., Hennessey J.V. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999, 159:79-82.
8. Chou K.M., Chiu S.Y., Chen C.H., et al. Correlation of clinical changes with regard to thyroxine replacement therapy in hypothyroid patients-focusing on the change of renal function. Kidney Blood Press Res 2011, 34:365-372.
9. Villabona C., Sahun M., Roca M., et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci 1999, 318:277-280.
10. HLAD C.J. Jr, Bricker N.S. Renal function and I131 clearance in hyperthyroidism and myxedema. J Clin Endocrinol Metab 1954, 14:1539-1550.
11. Karanikas G., Schutz M., Szabo M., et al. Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol 2004, 24:41-45.
12. Shin D.H., Lee M.J., Kim S.J., et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab 2012, 97:2732-2740.
13. Shin D.H., Lee M.J., Lee H.S., et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013, 23:654-661.
14. Meuwese C.L., Dekkers O.M., Stenvinkel P., et al. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol 2013, 9:599-609.
15. Zoccali C., Benedetto F., Mallamaci F., et al. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens 2006, 24:2039-2046.
16. Bengel F.M., Nekolla S.G., Ibrahim T., et al. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. Journal of Clin Endocrinol Metab 2000, 85:1822-1827.
17. Vargas F., Moreno J.M., Rodriguez-Gomez I., et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006, 154:197-212.
18. Moreno J.M., Wangensteen R., Sainz J., et al. Role of endothelium-derived relaxing factors in the renal response to vasoactive agents in hypothyroid rats. Am J Physiol Endocrinol Metab 2003, 285:E182-E188.
19. Allon M., Harrow A., Pasque C.B., et al. Renal sodium and water handling in hypothyroid patients: the role of renal insufficiency. J Am Soc Nephrol 1990, 1:205-210.
20. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003, 88:2438-2444.
21. Sato K., Okamura K., Yoshinari M., et al. Reversible primary hypothyroidism and elevated serum iodine level in patients with renal dysfunction. Acta Endocrinol (Copenh) 1992, 126:253-259.
22. Meuwese C.L., Snaedal S., Halbesma N., et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-{alpha} are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 2011, 26:1313-1318.
23. Warner M.H., Beckett G.J. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 2010, 205:1-13.
24. Peeters R.P., Wouters P.J., Kaptein E., et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003, 88:3202-3211.
25. Feingold K., Kim M.S., Shigenaga J., et al. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 2004, 286:E201-E207.
26. Carrero J.J., Stenvinkel P., Cuppari L., et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr 2013, 23:77-90.
27. Abo-Zenah H.A., Shoeb S.A., Sabry A.A., et al. Relating circulating thyroid hormone concentrations to serum interleukins-6 and -10 in association with non-thyroidal illnesses including chronic renal insufficiency. BMC Endocr Disord 2008, 8:1.
28. Wiederkehr M.R., Kalogiros J., Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1190-1197.
29. Naeije R., Golstein J., Clumeck N., et al. A low T3 syndrome in diabetic ketoacidosis. Clin Endocrinol (Oxf) 1978, 8:467-472.
30. Wilber J.F., Utiger R.D. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest 1969, 48:2096-2103.
31. Wiersinga W.M., Touber J.L. The influence of beta-adrenoceptor blocking agents on plasma thyroxine and triiodothyronine. J Clin Endocrinol Metab 1977, 45:293-298.
32. Miyashita K., Murakami M., Iriuchijima T., et al. Regulation of rat liver type 1 iodothyronine deiodinase mRNA levels by testosterone. Mol Cell Endocrinol 1995, 115:161-167.
33. Napolitano G., Bonomini M., Bomba G., et al. Thyroid function and plasma selenium in chronic uremic patients on hemodialysis treatment. Biol Trace Elem Res 1996, 55:221-230.
34. Yilmaz M.I., Sonmez A., Karaman M., et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol 2011, 33:25-32.
35. Rhee C.M., Alexander E.K., Bhan I., et al. Hypothyroidism and mortality among dialysis patients. Clin J Am Soc Nephrol 2013, 8:593-601.
36. Meuwese C.L., Carrero J.J., Cabezas-Rodriguez I., et al. Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. J Intern Med 2013, 274:584-593.
37. Carrero J.J., Qureshi A.R., Axelsson J., et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 2007, 262:690-701.
38. Meuwese C.L., Dekker F.W., Lindholm B., et al. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2012, 7:131-138.
39. Tatar E., Kircelli F., Asci G., et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:2240-2246.
40. Ozen K.P., Asci G., Gungor O., et al. Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol 2011, 33:305-312.
41. Raff H., Trivedi H. Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr Connect 2012, 2:23-31.
42. Wallace E.Z., Rosman P., Toshav N., et al. Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility. J Clin Endocrinol Metab 1980, 50:46-51.
43. Si J., Ge Y., Zhuang S., et al. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int 2013, 83:635-646.
44. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2012, 8:122-128.
45. Iwashima F., Yoshimoto T., Minami I., et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008, 149:1009-1014.
46. Leopold J.A., Dam A., Maron B.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nature Med 2007, 13:189-197.
47. Garnier A., Bendall J.K., Fuchs S., et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004, 110:1819-1825.
48. Endemann D.H., Touyz R.M., Iglarz M., et al. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004, 43:1252-1257.
49. N'Gankam V., Uehlinger D., Dick B., et al. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int 2002, 61:1859-1866.
50. Drechsler C., Ritz E., Tomaschitz A., et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European heart journal 2013, 34:578-587.
51. Funder J.W. Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2009, 53:286-290.
52. Henschkowski J., Stuck A.E., Frey B.M., et al. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. Am J Hypertens 2008, 21:644-649.
53. Tomaszewski M., Charchar F.J., Maric C., et al. Inverse associations between androgens and renal function: the Young Men Cardiovascular Association (YMCA) study. Am J Hypertens 2009, 22:100-105.
54. Fukui M., Kitagawa Y., Kamiuchi K., et al. Low serum dehydroepiandrosterone sulfate concentration is a predictor for deterioration of urinary albumin excretion in male patients with type 2 diabetes. Diabetes Res Clin Pract 2006, 73:47-50.
55. Kakiya R., Shoji T., Hayashi T., et al. Decreased serum adrenal androgen dehydroepiandrosterone sulfate and mortality in hemodialysis patients. Nephrol Dial Transplant 2012, 27:3915-3922.
56. Hsu H.J., Yen C.H., Chen C.K., et al. Low plasma DHEA-S increases mortality risk among male hemodialysis patients. Exp Gerontol 2012, 47:950-957.
57. Kawano H., Yasue H., Kitagawa A., et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003, 88:3190-3195.
58. Altman R., Motton D.D., Kota R.S., et al. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol 2008, 48:76-84.
59. Jahn M.P., Gomes L.F., Jacob M.H., et al. The effect of dehydroepiandrosterone (DHEA) on renal function and metabolism in diabetic rats. Steroids 2011, 76:564-570.
60. Hou S.H., Grossman S., Molitch M.E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985, 6:245-249.
61. Cowden E.A., Ratcliffe W.A., Ratcliffe J.G., et al. Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxf) 1978, 9:241-248.
62. Yavuz D., Topcu G., Ozener C., et al. Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy. Clin Endocrinol (Oxf) 2005, 63:520-524.
63. Veldhuis J.D., Iranmanesh A., Wilkowski M.J., et al. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur J Endocrinol 1994, 131:489-498.
64. Stumpe K.O., Kolloch R., Higuchi M., et al. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control. Lancet 1977, 2:211-214.
65. Raaz D., Wallaschofski H., Stumpf C., et al. Increased prolactin inacute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression. Horm Metab Res 2006, 38:767-772.
66. Wallaschofski H., Lohmann T., Hild E., et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 2006, 96:38-44.
67. Wallaschofski H., Eigenthaler M., Kiefer M., et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003, 23:479-483.
68. Marlettini M.G., Cassani A., Morselli Labate A.M., et al. Role of prolactin in pregnancy hypertension. Clin Exp Hypertens A 1987, 9:1099-1119.
69. Leanos-Miranda A., Marquez-Acosta J., Cardenas-Mondragon G.M., et al. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab 2008, 93:2492-2499.
70. Corona G., Rastrelli G., Boddi V., et al. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl 2011, 34:217-224.
71. Reuwer A.Q., Twickler M.T., Hutten B.A., et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet 2009, 2:389-395.
72. Carrero J.J., Kyriazis J., Sonmez A., et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012, 7:207-215.
73. Francis K., Lewis B.M., Akatsu H., et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J 2003, 17:2266-2268.
74. Sauro M.D., Buckley A.R., Russell D.H., Fitzpatrick D.F. Prolactin stimulation of protein kinase C activity in rat aortic smooth muscle. Life Sci 1989, 44:1787-1792.
75. Aziz M.M., Ishihara S., Rumi M.A., et al. Prolactin induces MFG-E8 production in macrophages via transcription factor C/EBPbeta-dependent pathway. Apoptosis 2008, 13:609-620.
76. Bresson J.L., Jeay S., Gagnerault M.C., et al. Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein. Endocrinology 1999, 140:3203-3209.
77. Sun R., Li A.L., Wei H.M., et al. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res 2004, 14:67-73.
78. Molinari C., Grossini E., Mary D.A., et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007, 148:4080-4090.
79. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128:589-600.
80. Parkes D. Drug therapy: bromocriptine. N Engl J Med 1979, 301:873-878.
81. Bommer J., Ritz E., del Pozo E., Bommer G. Improved sexual function in male haemodialysis patients on bromocriptine. Lancet 1979, 2:496-497.
82. Mejia-Rodriguez O., Alvarez-Aguilar C., Vega-Gomez H.E., et al. Bromocriptine induces regression of left ventricular hypertrophy in peritoneal dialysis patients. Proc West Pharmacol Soc 2005, 48:122-125.
83. Mejia-Rodriguez O., Alvarez-Aguilar C., Ledesma-Ramirez M., et al. Therapeutic effect of bromocriptine together with the established treatment for hypertension in patients undergoing peritoneal dialysis. Proc West Pharmacol Soc 2004, 47:122-124.
84. Degli Esposti E., Sturani A., Santoro A., et al. Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Clin Sci (Lond) 1985, 69:51-56.
85. Carrero J.J. Gender differences in chronic kidney disease: underpinnings and therapeutic implications. Kidney Blood Press Res 2010, 33:383-392.
86. Stringer K.D., Komers R., Osman S.A., et al. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int 2005, 68:1729-1739.
87. Elliot S.J., Berho M., Korach K., et al. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int 2007, 72:464-472.
88. Maric C., Sandberg K., Hinojosa-Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004, 15:1546-1556.
89. Catanuto P., Doublier S., Lupia E., et al. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int 2009, 75:1194-1201.
90. Ahmed S.B., Hovind P., Parving H.H., et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005, 28:1988-1994.
91. Agarwal M., Selvan V., Freedman B.I., et al. The relationship between albuminuria and hormone therapy in postmenopausal women. Am J Kidney Dis 2005, 45:1019-1025.
92. Szekacs B., Vajo Z., Varbiro S., et al. Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000, 107:1017-1021.
93. Monster T.B., Janssen W.M., de Jong P.E., et al. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 2001, 161:2000-2005.
94. Ahmed S.B., Culleton B.F., Tonelli M., et al. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008, 74:370-376.
95. Stehman-Breen C.O., Gillen D., Gipson D. Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int 1999, 56:2243-2247.
96. Lim V.S., Henriquez C., Sievertsen G., et al. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 1980, 93:21-27.
97. Anantharaman P., Schmidt R.J. Sexual function in chronic kidney disease. Adv Chronic Kidney Dis 2007, 14:119-125.
98. Palmer B.F. Sexual dysfunction in uremia. J Am Soc Nephrol 1999, 10:1381-1388.
99. Weisinger J.R., Bellorin-Font E. Outcomes associated with hypogonadism in women with chronic kidney disease. Adv Chronic Kidney Dis 2004, 11:361-370.
100. Carrero J.J., de Jager D.J., Verduijn M., et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clin J Am Soc Nephrol 2011, 6:1722-1730.
101. Weisinger J.R., Gonzalez L., Alvarez H., et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 2000, 58:331-335.
102. Hernandez E., Valera R., Alonzo E., et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 2003, 63:2269-2274.
103. Shiraki N., Nakashima A., Doi S., et al. Low serum testosterone is associated with atherosclerosis in postmenopausal women undergoing hemodialysis. Clin Exp Nephrolt 2013, Jul 26. [Epub ahead of print].
104. Ji H., Menini S., Mok K., et al. Gonadal steroid regulation of renal injury in renal wrap hypertension. Am J Physiol Renal Physiol 2005, 288:F513-F520.
105. Cho M.H., Jung K.J., Jang H.S., et al. Orchiectomy attenuates kidney fibrosis after ureteral obstruction by reduction of oxidative stress in mice. Am J Nephrol 2012, 35:7-16.
106. Metcalfe P.D., Leslie J.A., Campbell M.T., et al. Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol 2008, 294:E435-E443.
107. Reckelhoff J.F., Zhang H., Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension 2000, 35:480-483.
108. Reckelhoff J.F., Yanes L.L., Iliescu R., et al. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 2005, 289:F941-F948.
109. Doublier S., Lupia E., Catanuto P., et al. Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 2011, 79:404-413.
110. Xu Q., Wells C.C., Garman J.H., et al. Imbalance in sex hormone levels exacerbates diabetic renal disease. Hypertension 2008, 51:1218-1224.
111. Haring R., Nauck M., Volzke H., et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am J Nephrol 2011, 33:209-217.
112. Lapi F., Azoulay L., Niazi M.T., et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA 2013, 310:289-296.
113. Molinari C., Battaglia A., Grossini E., et al. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 2002, 543:365-372.
114. Soljancic A., Ruiz A.L., Chandrashekar K., et al. Protective role oftestosterone in ischemia-reperfusion-induced acute kidney injury. Am J Physiol Regul Integr Comp Physiol 2013, 304:R951-R958.
115. Yilmaz M.I., Sonmez A., Qureshi A.R., et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:1617-1625.
116. Carrero J.J., Qureshi A.R., Nakashima A., et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011, 26:184-190.
117. Glass A.R., Beach J., Vigersky R.A. Hypogonadotropic hypogonadism in nephrotic rats: increased sensitivity to negative feedback effects of testosterone. Metabolism 1985, 34:574-579.
118. Carrero J.J., Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant 2012, 27:4030-4041.
119. Iglesias P., Carrero J.J., Diez J.J. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 2012, 25:31-42.
120. Carrero J.J., Qureshi A.R., Parini P., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009, 20:613-620.
121. Gungor O., Kircelli F., Carrero J.J., et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?. Clin J Am Soc Nephrol 2010, 5:2018-2023.
122. Bello A.K., Stenvinkel P., Lin M., et al. Serum testosterone levels and clinical outcomes in male hemodialysis patients. Am J Kidney Dis 2013, Jul 26. [Epub ahead of print].
123. Carrero J.J., Barany P., Yilmaz M.I., et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant 2012, 27:709-715.
124. Cigarrán S., Pousa M., Castro M.J., et al. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. J Renal Nutr 2013, 23:e89-e95.
125. Richardson J.R., Weinstein M.B. Erythropoietic response of dialyzed patients to testosterone administration. Ann Intern Med 1970, 73:403-407.
126. Johansen K.L., Mulligan K., Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999, 281:1275-1281.
127. Chidsey C.A., Harrison D.C., Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962, 267:650-654.
128. Waagstein F., Hjalmarson A., Varnauskas E., et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975, 37:1022-1036.
129. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
130. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435. Effects of enalapril on mortality in severe congestive heart failure.
131. Carrero J.J., Park S.H., Axelsson J., et al. Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad. Semin Dial 2009, 22:381-386.
132. Meuwese C.L., Stenvinkel P., Dekker F.W., et al. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol 2011, 7:166-176.
133. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
134. Fukata J., Imura H., Nakao K. Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function. J Endocrinol Invest 1994, 17:141-155.
135. Jones T.H., Kennedy R.L. Cytokines and hypothalamic-pituitary function. Cytokine 1993, 5:531-538.
136. Carrero J.J., Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009, 4(suppl 1):S49-S55.
137. Spath-Schwalbe E., Born J., Schrezenmeier H., et al. Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994, 79:1212-1214.